Amedisys, Inc. (NASDAQ:AMED) Short Interest Update

Amedisys, Inc. (NASDAQ:AMED) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,260,000 shares, an increase of 37.8% from the October 15th total of 1,640,000 shares. Currently, 7.1% of the shares of the stock are sold short. Based on an average daily volume of 387,600 shares, the short-interest ratio is currently 5.8 days.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on AMED shares. Deutsche Bank Aktiengesellschaft lowered Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price target on the stock. in a research report on Monday, July 29th. Cantor Fitzgerald restated a “neutral” rating and set a $101.00 price target on shares of Amedisys in a research note on Thursday, July 25th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $100.67.

Amedisys Trading Down 0.6 %

Shares of AMED opened at $90.49 on Thursday. Amedisys has a 52-week low of $89.55 and a 52-week high of $98.95. The company has a market cap of $2.96 billion, a price-to-earnings ratio of 35.91, a PEG ratio of 1.87 and a beta of 0.78. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The stock has a fifty day moving average price of $96.32 and a two-hundred day moving average price of $95.85.

Amedisys (NASDAQ:AMED) last released its earnings results on Wednesday, November 6th. The health services provider reported $1.00 EPS for the quarter, missing the consensus estimate of $1.19 by ($0.19). The firm had revenue of $587.67 million during the quarter, compared to analyst estimates of $586.75 million. Amedisys had a net margin of 3.57% and a return on equity of 12.20%. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. During the same period last year, the business posted $0.98 earnings per share. Analysts predict that Amedisys will post 4.66 EPS for the current fiscal year.

Institutional Trading of Amedisys

A number of institutional investors and hedge funds have recently modified their holdings of the stock. KBC Group NV bought a new position in Amedisys in the third quarter valued at approximately $63,000. Innealta Capital LLC bought a new position in Amedisys during the second quarter worth about $64,000. Covestor Ltd raised its stake in Amedisys by 134.2% in the first quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock valued at $72,000 after buying an additional 447 shares during the period. Signaturefd LLC lifted its position in shares of Amedisys by 88.2% in the second quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock valued at $104,000 after buying an additional 530 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Amedisys by 14.5% during the 3rd quarter. CWM LLC now owns 2,190 shares of the health services provider’s stock worth $211,000 after acquiring an additional 277 shares during the period. 94.36% of the stock is owned by institutional investors.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.